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Introduction
Productive HIV assembly requires the coordinated mobiliza­
tion of both viral and cellular host factors toward the plasma 
membrane (PM) domains where formation of viral particles 
takes place. This process is orchestrated by the viral precursor 
protein Pr55Gag, a myristoylated polyprotein that contains four 
major structural domains: matrix, capsid, nucleocapsid, and p6. 
A highly basic region present in the matrix domain is res­
ponsible for binding to phosphatidylinositol 4,5­bisphosphate 
(PI(4,5)P2), a phosphoinositide present at the inner leaflet of the 
PM. Upon binding PI(4,5)P2, Pr55Gag molecules multimerize and 
form a spherical shell that packages the genomic RNA into the 
nascent virion. Concomitantly, the viral envelope protein Env is 
recruited and incorporated into the nascent viral particles. During 
virus release, the viral protease cleaves Pr55Gag into its constituent 
During the late stages of the HIV-1 replication cycle, the viral polyprotein Pr55Gag is recruited to the plasma membrane (PM), where it binds phospha-
tidylinositol 4,5-bisphosphate (PI(4,5)P2) and directs HIV-1 
assembly. We show that Rab27a controls the trafficking 
of late endosomes carrying phosphatidylinositol 4-kinase 
type 2  (PI4KII) toward the PM of CD4+ T cells. Hence, 
Rab27a promotes high levels of PM phosphatidylinositol 
4-phosphate and the localized production of PI(4,5)P2, there-
fore controlling Pr55Gag membrane association. Rab27a 
also controls PI(4,5)P2 levels at the virus-containing com-
partments of macrophages. By screening Rab27a effectors, 
we identified that Slp2a, Slp3, and Slac2b are required 
for the association of Pr55Gag with the PM and that Slp2a 
cooperates with Rab27a in the recruitment of PI4KII to 
the PM. We conclude that by directing the trafficking of 
PI4KII-positive endosomes toward the PM, Rab27a controls 
PI(4,5)P2 production and, consequently, HIV-1 replication.
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the cells through endocytosis (Naldini et al., 1996), the two 
Rab27a shRNA sequences significantly impaired HIV­1 rep­
lication, as determined by reduced production of p24 antigen 
at day 5 postinfection (p.i.; Fig. 1 B). Given that the strongest 
effect on Rab27a mRNA silencing was observed with shRNA 
sequence #2, this construct was chosen for the next set of exper­
iments. The ability of shRNA#2 to silence Rab27a expression 
was confirmed by immunoblotting (Fig. 1 C). The percentage 
of live cells in control and Rab27a­silenced cells, evaluated 
by Annexin V/propidium iodide staining, showed that Rab27a 
silencing did not affect cell viability (Fig. 1 D). To rule out 
off­target effects of the shRNA treatment, we rescued Rab27a 
expression in Rab27a­silenced cells and observed a reversion of 
the inhibition in HIV­1 replication (Fig. S1, A and B), confirm­
ing the specificity of the results.
The kinetics of HIV­1 production was then evaluated by 
infecting Jurkat cells with a CXCR4­tropic HIV­1 strain (IIIb) 
at a low MOI. In these experimental conditions, HIV­1 rep­
lication in Rab27a­silenced cells was also severely impaired 
(Fig. 1, E, F, and G).
Further experiments were performed to assess whether 
Rab27a was required for early or late stages of the viral replica­
tion cycle. The lack of differences between control and Rab27a­
silenced cells in (a) cell surface levels of CD4 and CXCR4 
(HIV­1 receptor and coreceptor, respectively; Fig. S2 A), (b) the 
amount of HIV­1 attached to the cell surface (measured after co­
incubating cells and virus at 4°C for 90 min) and internalized 
(measured after coincubating cells and virus at 37°C; Fig. S2 B), 
and (c) the susceptibility to HIV­1 infection in a single­cycle 
assay (Fig. S2, C and D) allowed us to conclude that Rab27a 
does not interfere with early steps of the HIV­1 replication cycle. 
To analyze the role of Rab27a in the late stages of the viral rep­
lication cycle, cells were spinoculated with HIV­1 at a high MOI 
to achieve a high percentage of infected cells at 48 h p.i. The 
amount of cell­associated Pr55Gag in control and Rab27a­silenced 
cells was similar, showing that, as in the case of wild­type HIV­1, 
the entry of VSV­G–pseudotyped viral particles is not affected 
in Rab27a­silenced cells (Fig. 1 H, left). However, the amount 
of virus released into the supernatant was dramatically reduced 
in Rab27a­silenced cells (Fig. 1 H, right), suggesting that the in­
hibition of HIV­1 replication observed in Rab27a­silenced cells 
is mainly caused by a defect in the assembly or release of viral 
particles. Taking into consideration that the host restriction fac­
tor tetherin inhibits HIV­1 release, we next decided to analyze 
whether Rab27a expression modified tetherin surface expression. 
Both in uninfected and in HIV­1–infected cells, tetherin expres­
sion in Rab27a­silenced cells was comparable to that of control 
cells (Fig. S2, E–H). Thus, silencing the expression of Rab27a 
impairs HIV­1 replication by controlling a tetherin­independent 
late step of the viral replication cycle.
We then analyzed the role of Rab27a in HIV­1 replication 
in primary CD4+ T cells by using two strategies. First, expres­
sion of Rab27a was silenced by transducing peripheral blood 
mononuclear cells (PBMCs) with Rab27a shRNA#2 (efficiency 
of silencing: 52%). In addition, PBMCs from a patient with a 
mutation in Rab27a, a clinical condition known as Griscelli syn­
drome (GS; Ménasché et al., 2005), and an age­matched healthy 
proteins, giving rise to mature infectious viral particles 
(Balasubramaniam and Freed, 2011; Sundquist and Kräusslich, 
2012). Whereas in CD4+ T cells, HIV­1 assembles at discrete 
domains of the PM, in macrophages, HIV­1 budding takes 
place in specialized, intracellular sequestered portions of the 
PM known as virus­containing compartments (VCCs; Deneka 
et al., 2007; Jouve et al., 2007; Welsch et al., 2007; Bennett 
et al., 2009; Benaroch et al., 2010). In both cases, the HIV­1 as­
sembly domains present a peculiar enrichment for a variety of 
tetraspanins, such as CD9, CD63, CD81, and CD82 (Booth et al., 
2006; Deneka et al., 2007; Jolly et al., 2011). However, the role 
played by tetraspanins at the site of HIV­1 assembly still remains 
an open question in the field.
The trafficking of late endosomes/secretory lysosome to­
ward the site of HIV­1 assembly has been shown to be required 
for the dissemination of HIV­1 infection in CD4+ T cells (Jolly 
et al., 2011). Indeed, cells isolated from Chediak–Higashi and 
Hermansky–Pudlack syndrome patients, two rare autosomal re­
cessive diseases that affect late endosomes/lysosomes, are defi­
cient in HIV­1 production (Dong et al., 2005; Jolly and Sattentau, 
2007). Moreover, several cellular proteins implicated in endo­
somal function have been shown to be required for Pr55Gag traf­
ficking (Balasubramaniam and Freed, 2011). Along these lines, 
it has been proposed that during viral assembly and release, 
HIV­1 hijacks the cellular exosome secretion pathway (Gould 
et al., 2003; Booth et al., 2006). Exosome secretion takes place 
after the fusion of the limiting membrane of multivesicular 
endosomes (MVEs) with the PM, resulting in the extracellu­
lar release of their intraluminal vesicles, which are then named 
as exosomes (Théry et al., 2009). We previously showed that 
small GTPases Rab27a and Rab27b control exosome secretion 
by promoting the docking of MVEs to the PM (Ostrowski et al., 
2010). Taking into consideration the role played by Rab27a in 
regulating the trafficking of late endosomes and exosome secre­
tion and the proposed link between these processes and HIV­1 
assembly, in this study, we undertook the analysis of the role 
played by late endosomal compartments in HIV­1 budding by 
using cells deficient in Rab27a.
We show that Rab27a controls the recruitment of PI4KII 
(phosphatidylinositol 4­kinase type 2 ) from endosomes to the 
PM, promoting high levels of phosphatidylinositol 4­phosphate 
(PI(4)P) and fueling PI(4,5)P2 production. This, in turn, favors 
the recruitment of Pr55Gag and HIV­1 assembly. We also show 
that Rab27a uses its effector Slp2a to promote PI4KII recruit­
ment and the production of PI(4)P and PI(4,5)P2 at the PM. In 
summary, our study identifies a Rab27a­controlled endosomal 
trafficking pathway usurped by HIV­1 during viral assembly.
Results
Silencing of Rab27a inhibits HIV-1 
replication in CD4+ T cells and macrophages
The role of Rab27a in HIV­1 replication was first analyzed 
by silencing the expression of this small GTPase in the CD4+ 
T cell line Jurkat by using two different Rab27a shRNA se­
quences (Fig. 1 A). Upon infection with a VSV­G–pseudotyped 
HIV­1 strain, which circumvents the viral receptors and enters 
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Rab27a controls the formation of the  
HIV-1 assembly platform and Gag 
recruitment to cell membranes in CD4+  
T cells and macrophages
Rab27 controls the intracellular trafficking of MVEs (Ostrowski 
et al., 2010) and of several lysosome­related organelles (LROs) 
in different cell types (Raposo et al., 2007). To explore whether 
the impairment of HIV­1 assembly observed in Rab27a­silenced 
cells was related to a defect in the trafficking of these organelles, 
donor were used. In agreement with results obtained in Jurkat 
cells, Rab27a­deficient lymphocytes produced significantly 
less virus, as compared with their respective controls (Fig. 1, 
I and J). Finally, the role of Rab27a in HIV­1 production was 
analyzed in primary macrophages. In this case too, we observed 
that Rab27a silencing (efficiency of silencing: >90%) impaired 
HIV­1 replication (Fig. 1 K). We conclude that Rab27a is re­
quired for a late step of the HIV­1 replication cycle, both in 
CD4+ T cells and monocyte­derived macrophages (MDMs).
Figure 1. Rab27a is required for HIV replication in CD4+ T lymphocytes and macrophages. (A–D) Jurkat cells were transduced with lentivirus encoding 
different Rab27a shRNA sequences (A and B; open bars), or a control scrambled shRNA (black bars). (A) Rab27a mRNA levels were determined by qPCR. 
Means ± SD of a representative experiment (n = 3) performed in triplicates is shown. (B) Cells (3 × 104/0.1 ml) were infected with a VSV-G–pseudotyped 
HIV (20 ng p24/ml), and p24 production was evaluated in cell supernatants at day 5 p.i. Means ± SD of two independent experiments expressed as 
percentages of p24 production of control cells are shown. (C) Immunoblot of Rab27a protein levels. Actin was used as a loading control. (D) Cell viability 
was determined at day 7 after puromycin selection by annexin V staining and propidium iodide exclusion followed by FACS analysis. Dot plots from a 
representative experiment (n = 4) are shown. Percentage of death cells (annexin V+/propidium iodide+) is indicated. (E–G) Control (closed circles) and 
Rab27a-silenced Jurkat cells (open circles; 3 × 104/0.1 ml) were infected with HIV (IIIb strain; 50 ng p24/ml). The production of p24 (E) and the percent-
ages of p24-positive cells (F and G) were determined by ELISA and FACS analysis, respectively. Representative dot plots (F) and the percentages of infected 
cells (G) from a representative experiment (n = 6) are shown. (H) Virus release assay. Cells were spinoculated with a high MOI of VSV-G–pseudotyped HIV 
strain. 48 h later, the amounts of cell-associated and released virus were analyzed by immunoblotting. (I and J) Control and Rab27a-silenced PBMCs (I) 
or PBMCs from a GS patient and an age-matched control (J) were infected with a VSV-G–pseudotyped HIV-1 (200 and 50 ng/ml p24, respectively). The 
production of p24 was evaluated at different days p.i. Results from a representative experiment (n = 3 and n = 2) performed in triplicates are expressed 
as the means ± SD. (K) Quantification of p24 antigen in cell supernatants from control (closed triangles) or Rab27a-silenced (open triangles) MDMs (5 × 
104/0.1 ml) infected with HIV-1(BaL strain; 50 ng p24/ml). Kinetics of p24 production from a representative experiment are shown in the left graph. p24 
production by cells from seven different blood donors at day 5 p.i. is shown in the right graph. Asterisks indicate statistically significant differences from 
the control: **, P < 0.01. KD, knockdown.
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Figure 2. Silencing of Rab27a impairs the recruitment of MVEs to the site of HIV-1 assembly and Pr55Gag association with the PM in Jurkat cells. (A) LSCM 
of live control and Rab27a-silenced cells stably expressing CD63-GFP and stained with LysoTracker. (B) FACS plots showing endogenous cell surface CD63 
levels in control and Rab27a-silenced cells. Isotype control is shown (gray line). The data shown are from a single representative experiment out of six 
repeats. For the experiment shown, 10,000 cells from each condition were analyzed. (C) Mean fluorescence intensity (MFI) of cell surface CD63 staining in 
control and Rab27a-silenced cells (n = 6). (D) Immunofluorescence LSCM images of endogenous CD63 and Gag in control and Rab27a-silenced infected 
Jurkat cells at day 12 p.i. To better visualize Gag cytosolic distribution in Rab27a-silenced cells, the laser power was increased for the acquisition of the 
green channel. (E) Quantitation of PM versus cytosolic distribution of Gag and of CD63 forming a PM cap versus its intracellular location in 100 cells of 
each condition. Data are expressed as percentages of cells in each category. (F) LSCM of control and Rab27a-silenced Jurkat cells. Cell surface CD81 
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we performed laser­scanning confocal microscopy (LSCM) in 
live cells using the tetraspanin CD63 and LysoTracker (a dye 
that labels acidic compartments) as markers of LRO/endo­
some identity. Rab27a­silenced cells presented a marked in­
crease in the size of GFP­CD63+ compartments concomitantly 
with a reduction in the amount of PM­associated CD63, as 
compared with control cells (Fig. 2 A). This phenotype could 
be reverted by the expression of exogenous Rab27a (Fig. S3, 
A and B). The reduction in PM levels of endogenous CD63 
was also indicated by FACS analysis (Fig. 2, B and C). To 
further analyze whether the reduction in PM levels of CD63 
in Rab27a­silenced cells was caused by a defect in the traf­
ficking of CD63+ endosomes, we performed a CD4+ T cell 
degranulation assay based on the quantification of CD63 cell 
surface translocation after stimulation of the cells with PMA­
ionomycin. Translocation of CD63 from internal compart­
ments to the PM was severely impaired in Rab27a­silenced 
cells (Fig. S3, C and D), suggesting that the Rab27a­regulated 
pathway of endosomal trafficking significantly contributes to 
PM levels of CD63. To rule out an effect of Rab27a on the 
functionality of the regular secretory pathway, the secretion 
of the cytokine granulocyte–macrophage colony­stimulating 
factor (GM­CSF; that follows the conventional secretory path­
way) was assessed by ELISA. No changes in the secretion 
of this cytokine were observed (Fig. S3 E), confirming previ­
ous results showing that Rab27a does not interfere with the 
regular secretory pathway of the cell (Ostrowski et al., 2010). 
Altogether, these results suggest that by controlling the traf­
ficking of CD63­positive endosomes/LROs, Rab27a promotes 
PM localization of CD63 in CD4+ T cells.
We next analyzed the Rab27a­mediated trafficking of 
CD63+ endosomes in HIV­1–infected cells by LSCM immuno­
fluorescence analysis. In agreement with a previous study 
(Jolly et al., 2011), we observed that in HIV­1–infected con­
trol cells, CD63 was redistributed from its predominantly 
internal localization toward a discrete, polarized domain of 
the PM, where it showed a high level of colocalization with 
Gag (Fig. 2 D). In contrast, in Rab27a­silenced cells, CD63+ 
endosomes remained scattered throughout the cytoplasm and 
the formation of a PM cap of CD63 was not observed. This 
alteration in endosomal trafficking was concomitant with a 
change in Gag distribution, which instead of being predomi­
nantly associated with the PM, acquired a cytosolic distribu­
tion. (Fig. 2, D and E). These changes were not caused by 
alterations in the production of Pr55Gag, as revealed by analy­
sis of the mean fluorescence intensity of Pr55Gag staining by 
FACS (mean fluorescence intensity of control cells = 5,848 ± 
215 vs. 5,695 ± 197 in Rab27a­silenced cells).
In addition to containing high levels of CD63, the site 
of HIV­1 assembly also presents an important enrichment in 
CD81 (Jolly and Sattentau, 2007; Krementsov et al., 2009), an­
other tetraspanin that, unlike CD63, is exclusively present at the 
PM of Jurkat cells and not in endosomes (Fig. S4 A). LSCM 
visualization of control cells revealed high levels of colocaliza­
tion between Pr55Gag and cell surface CD81 in patched regions 
of the PM (Fig. 2, F and G). In contrast, as mentioned in the pre­
vious paragraph, in Rab27a­silenced cells, Gag exhibited a pre­
dominantly cytosolic distribution. In addition, despite the fact 
that CD81 distribution in uninfected Rab27a­silenced CD4+  
T cells was comparable to that of control cells (Fig. S4 B), the 
HIV­1–induced coalescence of CD81 into discrete domains 
at the PM was inhibited in cells deficient for Rab27a (Fig. 2, 
F and G). These results suggest that Rab27a is required for the 
proper targeting of Pr55Gag to the PM and for the reorganization 
of the tetraspanin­enriched microdomains (TEMs).
The decrease in the association of Pr55Gag with the PM in 
Rab27a­silenced cells was confirmed by immunoblot analysis of 
Pr55Gag distribution in cytosolic and membrane fractions (Fig. 2, 
H and I). Interestingly, the p24 capsid protein was detected in 
association with cell membranes in control cells (likely repre­
senting mature viral particles in the process of budding) but not 
in Rab27a­silenced cells (Fig. 2 H, longer exposure).
We then decided to analyze Pr55Gag distribution in Rab27a­
deficient primary cells. The use of cells from a GS patient 
recapitulated the phenotype observed in Jurkat cells, further 
confirming that Rab27a is required for Pr55Gag membrane as­
sociation (Fig. 3, A and B). Finally, Pr55Gag distribution was 
analyzed in MDMs. In agreement with previous studies (Raposo 
et al., 2002; Ono et al., 2004; Deneka et al., 2007), we found 
that in control MDMs, Gag was noticeably concentrated in 
discrete apparently intracellular compartments, usually identi­
fied as VCCs, showing a high degree of colocalization with 
CD81 (Fig. 3 C, top). In contrast, in Rab27a­silenced MDMs, 
Gag exhibited a diffuse, cytosolic staining pattern (Fig. 3, 
C [bottom] and D).
Rab27a silencing does not disrupt Env 
trafficking and processing
Whereas Pr55Gag is recruited from the cytosol directly to the 
HIV­1 assembly site at the PM, Env reaches the PM through 
the regular ER–Golgi­dependent secretory pathway (Checkley 
et al., 2011). To rule out an effect of Rab27a in Env trafficking, 
the expression of total and cell surface Env was determined 
by FACS analysis in Jurkat cells at day 10 p.i. Consistent with 
the defect in HIV­1 replication shown in Fig. 1, the percentage 
of HIV­infected (Env positive) cells was lower in Rab27a­ 
silenced cells (Fig. 4, A and B). However, the mean fluorescence 
intensity of both total and cell surface Env in infected cells 
was similar in both conditions (Fig. 4, A and B), indicating that 
Env expression and trafficking to the PM were not perturbed 
was stained in nonpermeabilized cells, and, subsequently, intracellular Gag was stained. (G) Quantitation of PM versus cytosolic distribution of Gag was 
evaluated in 100 cells of each condition. Data are expressed as percentages of cells in each category. (H) Immunoblots of cell fractions to analyze the 
distribution of Pr55Gag and p24. The purity of the fractions was assessed by detection of the cytosolic protein GAPDH and the membrane-associated protein 
calnexin. M, membrane fraction; C, cytosolic fraction. One representative experiment out of three is shown. (I) Ratio of cytosol/membrane distribution of 
p55, corresponding to three independent experiments. In A, D, and F, transmitted light channel is shown on the right. The quantifications shown in E and 
G were performed by blinded observers on a per cell basis. KD, knockdown. **, P < 0.01; ***, P < 0.001. Bars, 2 µm.
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Indeed, silencing of Rab27a expression abrogated the polarized 
distribution of Gag at zones of cell­to­cell contact in Jurkat cells 
(Fig. 5, A and B). A similar phenotype was observed in primary 
CD4+ T cells isolated from a GS patient (Fig. 5 C) and in MDMs 
incubated with autologous activated PBMCs (Fig. 5 D).
To measure cell­to­cell transmission of HIV­1, the per­
centage of HIV­1–infected control or Rab27a­silenced cells at 
day 10 p.i. was determined by FACS. Because the percentage 
of HIV­1–infected cells was higher in control cells than in 
Rab27a­silenced cells, we normalized the percentage of HIV­1–
infected cells in each condition by adding noninfected con­
trol cells to cultures of HIV­1–infected control cells to have 
6% of HIV­infected cells in a total of 80,000 cells for each 
condition. (Fig. 5 E, left, donor cells). Cells were then added 
to cultures of GHOST cells (target), either in direct contact or 
separated by a filter membrane with pores that allow the pas­
sage of HIV­1 particles but not of cells. Silencing Rab27a ex­
pression impaired HIV­1 transmission both through cell–cell 
contact and through free viral particles (Fig. 5 E, right). These 
results indicate that Rab27a is required for the formation of 
virological synapses in both MDMs and CD4+ T cells and for 
HIV­1 cell­to­cell transmission in CD4+ T cells.
Rab27a controls the levels of PI(4,5)P2 in the 
PM of CD4+ T cells and in macrophage VCCs
Targeting of Pr55Gag to the PM is directed by PI(4,5)P2 (Ono 
et al., 2004). Thus, we sought to investigate whether the reduc­
tion in Pr55Gag association with the PM in Rab27a­silenced 
cells was caused by a reduction in PM levels of PI(4,5)P2. 
by Rab27a silencing. Indeed, LSCM analysis showed that in 
both control and Rab27a­silenced cells, Env exhibited a simi­
lar distribution, being present both in intracellular compart­
ments and at the PM (Fig. 4 C). Moreover, the proteolytic 
processing of gp160 by furin or furin­like proteases located 
in the Golgi (Checkley et al., 2011), evaluated as the ratio of 
gp41/gp160, was similar in control and Rab27a­silenced cells 
(Fig. 4, D and E), further indicating that Env processing at 
the Golgi is not altered upon Rab27a silencing. Finally, the 
infectivity of the viral particles still produced by Rab27a­silenced 
cells was assessed by infecting the reporter cell line GHOST 
with equal amounts of HIV­1 secreted by control and Rab27a­
silenced cells. The lack of difference in the infectivity of HIV­1 
particles produced by control and Rab27a­silenced cells pro­
vided functional evidence supporting the notion that Env in­
corporation into viral particles was not modified upon Rab27a 
silencing (Fig. 4 F). Altogether, these results indicate that Rab27a 
specifically regulates Pr55Gag trafficking without affecting the 
arrival of Env to the PM.
Formation of virological synapses and  
cell-to-cell transmission of HIV-1 are 
inhibited in Rab27a-deficient cells
Direct cell­to­cell transfer of HIV­1 is a more efficient way of 
propagating the infection, as compared with transmission by 
cell­free viral particles (Dimitrov et al., 1993; Carr et al., 1999). 
Our results anticipate that, by preventing Pr55Gag from reaching 
the PM, silencing of Rab27a will also limit both the amount of 
Pr55Gag at the virological synapse and cell–cell transfer of HIV­1. 
Figure 3. Rab27a controls Pr55Gag recruit-
ment to cell membranes in CD4+ T cells and 
macrophages. (A) 3D deconvolution fluor-
escence microscopy of HIV-1–infected PBMCs 
from a healthy control or a GS patient stained 
at day 4 p.i. with anti-p24 (green) and anti-
CD81 antibodies. Shown is a 3D maximum 
intensity projection of 10 optical sections ac-
quired at 0.2-µm intervals. (B) Quantitation of 
PM versus cytosolic distribution of Gag was 
evaluated by blinded observers on a per-cell 
basis, in 100 cells of each condition. Data 
are expressed as percentages of cells in each 
category. (C) LSCM of HIV-1–infected control 
or Rab27a-silenced MDMs stained at day 5 
p.i. with anti-p24 (green) and anti-CD81 anti-
bodies. (D) Quantification of Gag distribution 
was performed as described in B. ***, P < 
0.001. KD, knockdown. Bars, 2 µm.
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Fig. 6 D), confirming that the amount of [32P]­labeled PI(4,5)P2 
was significantly lower in Rab27a­silenced cells (Fig. 6 E). 
Paralleling the results obtained in Jurkat cells, silencing 
of Rab27a in primary CD4+ T cells also resulted in a signifi­
cant loss of PH­GFP staining at the PM (Fig. 6, F and G). 
Finally, PI(4,5)P2 distribution was analyzed in Rab27a­silenced 
MDMs. In agreement with previous studies (Mlcochova et al., 
2013), in control cells, PI(4,5)P2 was enriched at the PM as 
well as in intracellular structures, which were also positive 
for CD81 (Fig. 6 H, top). In contrast, in Rab27a­silenced 
The intracellular distribution of PI(4,5)P2 was evaluated by 
LSCM in Jurkat cells transduced with a GFP­tagged pleck­
strin homology (PH) domain derived from phospholipase C1 
(PH­GFP; Várnai and Balla, 1998). Staining of cell surface 
CD81 in nonpermeabilized cells was used to better define 
the localization of the PM. PH­GFP labeling of the PM 
was considerably reduced in Rab27a­silenced cells (Fig. 6, 
A–C). To assess global cellular levels of PI(4,5)P2 biochemically, 
the amount of [32P]orthophosphate incorporated into PI(4,5)P2 
molecules was analyzed by thin layer chromatography (TLC; 
Figure 4. Rab27a silencing does not disrupt 
Env trafficking. Control and Rab27a-silenced 
cells were infected with HIV (IIIb strain) and 
analyzed at day 10 p.i. (A) Representative 
FACS plot showing Total (top) and cell surface 
(bottom) Env levels in uninfected, control, and 
Rab27a-silenced cells. The percentage of Env-
positive cells in the gate containing Env-positive 
cells is indicated. (B) Quantification of FACS 
data from three independent experiments. 
(C) LSCM of control and Rab27a-silenced 
Jurkat cells stained with anti-p24 (green) and 
anti-Env antibodies. Differential interference 
contrast (DIC) images are shown on the 
right. Bars, 2 µm. (D) gp41 immunoblot on 
cells spinoculated with a high MOI of vesicular 
stomatitis virus–pseudotyped HIV at day 3 p.i. 
(E) gp41/gp160 ratio in control and Rab27a-
silenced cells (n = 2). (F) Infectivity of the viri-
ons produced by control and Rab27a-silenced 
cells was evaluated using the same amount of 
p24 (10 ng, as determined by ELISA) to infect 
GHOST cells (n = 3). Results are normalized 
to the value obtained by infecting GHOST 
cells with the virus contained in the superna-
tant of control cells. Error bars show SDs. KD, 
knockdown; MFI, mean fluorescence intensity. 
**, P < 0.01. Bars, 2µm.
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Rab27a controls PM levels of PI(4)P and 
the recruitment of PI4KII to the PM
To gain further mechanistic insight, the subcellular distribution 
of PI(4)P (a precursor in PI(4,5)P2 biosynthesis; Doughman 
et al., 2003) was analyzed in cells expressing the PI(4)P biosen­
sor GFP­P4M (Hammond et al., 2014). In control Jurkat cells, 
PI(4)P was detected at the PM as well as in intracellular vesi­
cles that likely represent endosomes and/or the Golgi complex 
(Fig. 7 A). Interestingly, in Rab27a­silenced cells, there was a se­
lective loss of PM PI(4)P (Fig. 7, A–C). Because of its previously 
described association with late endosomes (Salazar et al., 2005; 
Minogue et al., 2006) and its role in PM PI(4)P production (Wei 
et al., 2002; Balla and Balla, 2006; Pizarro­Cerdá et al., 2007; 
macrophages, PH­GFP and CD81, did not label any intra­
cellular compartment (Fig. 6, H and I). These changes in 
PI(4,5)P2 distribution were accompanied by the presence of 
PM patches containing both PI(4,5)P2 and CD81. Examination 
of the phase contrast image of the same cell reveals that these 
patches were located in thicker parts of the PM, thus likely rep­
resenting areas of stronger fluorescence signal.
Confirming the specificity of the phenotype described in 
this section, rescue experiments performed in Jurkat cells re­
verted the decrease in PM levels of PI(4,5)P2 (Fig. 6 J). Alto­
gether, results presented in this section indicate that Rab27a 
regulates PI(4,5)P2 levels in the PM of CD4+ T cells and in 
VCCs of MDMs.
Figure 5. Formation of the virological syn-
apse and cell-to-cell transmission of HIV are 
impaired in Rab27a-deficient cells. (A) Control 
or Rab27a-silenced Jurkat cells were infected 
with HIV (IIIB strain). At day 7 p.i., cells were 
plated onto poly-l-lysine–coated coverslips and 
incubated with noninfected target Jurkat cells 
for 1.5 h. Gag was stained with anti-p24 
antibodies and polarization of Gag at the vi-
rological synapses was evaluated by LSCM. 
Representative confocal and DIC images are 
shown. (B) Quantification of the number of cells 
showing a polarized distribution of Gag (30 
cell conjugates from two independent experi-
ments). (C and D) The ability of primary CD4+ 
T cells from a GS patient and the correspond-
ing healthy control (C) and Rab27a-silenced 
or control MDMs co-cultured with autologous 
CD4+ T cells to form virological synapses 
(D) was also evaluated by 3D deconvolution 
fluorescence microscopy and LSCM, respec-
tively. Representative confocal and DIC im-
ages are shown. In C, a 3D maximum intensity 
projection of 10 optical sections acquired 
at 0.2-µm intervals is shown. (E) 4,800 HIV- 
infected control or Rab27a-silenced Jurkat cells 
present in a total of 80,000 cells (Donor cells, 
left) were added to GHOST cell cultures either 
allowing direct interaction or separated by 
a 0.2-µm pore filter (transwell). After 1.5 h 
of co-culture, cells were removed, and the 
percentage of GFP-positive GHOST cells was 
determined by FACS analysis 48 h later. 
FSC-H, forward scatter height. The boxes con-
tain GFP-positive cells. Histograms show the 
means ± SD of three experiments performed 
in triplicates. *, P < 0.01; ***, P < 0.001. 
KD, knockdown. Bars, 2 µm.
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Figure 6. Silencing of Rab27a reduces PI(4,5)P2 levels in the PM of CD4+ T cells and in VCCs of macrophages. (A) LSCM visualization of PH-GFP in control 
and Rab27a-silenced Jurkat cells. Cell surface CD81 was labeled in nonpermeabilized cells and used as a reference of PM localization. Boxes indicate 
areas magnified on the right. (B) Representative single-cell intensity profile plots of the fluorescence of PH-GFP and CD81 at the PM quantified in a confocal 
slice along a line located on a representative segment of the cell (indicated with a scattered white line in the zoom shown in A). (C) Quantification of the 
localization of the PH-GFP signal predominantly at the PM or the cytosol in control and Rab27a-silenced cells was performed by blinded observers on a 
per-cell basis, in 200 cells of each condition. Data are expressed as percentages of cells in each category. (D) Incorporation of 32P in phosphoinositides 
was evaluated by TLC separation of lipid extracts from cells pulsed with [32P]orthophosphate. Shown is a representative autoradiograph. Positions of 
(phosphatidylinositol monophosphates [PIP]) and PI(4,5)P2 standards are indicated. (E) Quantification of the relative amounts of different phosphoinositides 
(n = 3). Error bars show SDs. (F) LSCM images of PH-GFP distribution in Rab27a-silenced primary CD4+ T cells isolated from blood. (G) Quantification of 
the localization of the PH-GFP signal predominantly at the PM or the cytosol of control and Rab27a-silenced CD4+ T cells. 200 cells were evaluated for 
each condition. (H) Representative LSCM images showing PH-GFP and CD81 distribution in control and Rab27a-silenced MDMs. (I) Quantification of the 
percentages of cells containing PH-GFP/CD81 double-positive structures in VCCs or at the peripheral PM. 90 cells were evaluated for each condition. 
(J and K) Restoring Rab27a expression in Jurkat cells expressing the 3UTR Rab27a shRNA rescues PI(4,5)P2 levels at the PM. (J) Representative images 
of PH-mRFP distribution in Rab27a-silenced cells (using the 3UTR shRNA) that were transduced (green cell) or not transduced with the Rab27a-encoding 
lentivirus. (K) Quantifications were performed by blinded observers on a per-cell basis, in ≥30 cells of each condition. Data are expressed as percentages 
of cells in each category. *, P < 0.01; ***, P < 0.001. KD, knockdown. Bars: (A [left], F, H, and J) 2 µm; (A, right) 1 µm.
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Pan et al., 2008), we hypothesized that Rab27a was required for 
the recruitment of PI4KII to the PM from endosomes. Indeed, 
in control cells, PI4KII was located at the PM as well as in intra­
cellular acidic (LysoTracker+) compartments (Fig. 7 D). In agree­
ment with previous studies (Berditchevski et al., 1997; Yauch 
and Hemler, 2000), we observed that PI4KII biochemically in­
teracted with CD63 (Fig. S5 A). Accordingly, we observed that 
both at the PM and in endosomes, PI4KII colocalized with CD63 
(Fig. 7 E). Live­cell visualization of cells expressing GFP­PI4KIIa 
and mCherry CD63 evidenced that some CD63/PI4KII double­
positive compartments presented rapid and long­range move­
ments. In particular, we observed vesicles that approached the 
PM where they seemed to dock for several seconds (Video 1 
and Fig. S5 B). Further suggesting a role of Rab27a in the traf­
ficking of PI4KII, we observed that both molecules colocalized 
in intracellular structures (Fig. S5 C).
Paralleling the alterations in CD63 distribution (Fig. 2), 
in Rab27a­silenced cells, PI4KII accumulated in enlarged 
Figure 7. Rab27a controls PM levels of PI(4)P and the CD63-mediated recruitment of PI4KII to the PM. (A) LSCM images of live control and Rab27a-
silenced Jurkat cells transiently transfected with GFP-P4M-SidM plasmid and observed 24 h later. (B) Representative single-cell intensity profile plots of the 
mean fluorescence intensity of GFP-P4M-SidM quantified in the selected regions indicated with a white rectangle shown in A. (C) Quantification of the 
localization of the GFP-P4M-SidM signal predominantly at the PM or the cytosol in control and Rab27a-silenced cells was performed by blinded observers 
on a per-cell basis, in 200 cells of each condition. (D) LSCM of live control and Rab27a-silenced Jurkat cells transiently transfected with PI4KII-GFP plasmid 
and labeled with LysoTracker red. (E) LSCM of live control and Rab27a-silenced Jurkat cells transiently transfected with PI4KII-GFP and mCherry-CD63 
plasmids. Manders correlation coefficient map is shown. Pseudocolored scale represents the contribution of each pixel to Manders colocalization coefficient 
(overlap coefficients for control and Rab27a-silenced cells: 0.74 ± 0.01 and 0.75 ± 0.02, respectively). Transmitted light images are shown on the right 
images of D and E. KD, knockdown. Bars, 2 µm.
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and S5 A). Interestingly, live­cell visualization showed that, as in 
the case of Rab27a­silenced cells, both molecules were present in 
enlarged endosomes that exhibited limited movement. Moreover, 
the presence of both molecules at the PM was markedly reduced 
(Video 3 and Fig. S5 B). Altogether, these observations show that 
Rab27a and Slp2a function together in the trafficking of PI4KII/
CD63­positive endosomes toward the PM, thus contributing to 
the generation of PI(4)P and a pool of PI(4,5)P2 that is required 
for HIV­1 assembly.
Discussion
In this study, we show that in CD4+ T cells, Rab27a controls the 
intracellular trafficking of PI4KII­positive late endosomes and 
the recruitment of this enzyme to the PM. Therefore, Rab27a 
promotes the production of PM PI(4)P and a pool of PI(4,5)P2 
required for Pr55Gag membrane association and HIV­1 assem­
bly. Moreover, we show that Rab27a regulates PI(4,5)P2 pro­
duction in the VCCs of macrophages. These results provide 
new information about the function of Rab27a and reveal that 
a common pathway regulated by Rab27a is required for HIV­1 
production in the two principal target cells of HIV­1 infection.
The main precursor for PI(4,5)P2 synthesis at the PM is 
PI(4)P, a product of the activity of a PI4­kinase acting on phos­
phatidylinositol (Doughman et al., 2003). Although in some cell 
types, PI(4)P production at the PM is performed by PI4KIII 
(Nakatsu et al., 2012), PI4KII has also been shown to control 
cellular levels of PI(4,5)P2 (Pan et al., 2008; Chu et al., 2010; 
Kang et al., 2013). Indeed, despite the fact that in several cell 
types PI4KII localizes primarily to the trans­Golgi network 
and endosomes (Wang et al., 2003; Salazar et al., 2005; Balla 
and Balla, 2006; Minogue et al., 2006), a portion of PI4KII 
can be recruited to the PM (Wei et al., 2002; Pizarro­Cerdá 
et al., 2007). In line with these observations, our results not only 
show that PI4KII is found in late endosomes but also that, by 
regulating the trafficking of these endosomes, Rab27a allows 
the recruitment of the enzyme to the PM of CD4+ T cells. Con­
sequently, Rab27a induces PI(4,5)P2 production, thus favoring 
the recruitment of Pr55Gag. After its association with the PM, 
Pr55Gag functions as a microdomain­organizing factor, inducing 
the coalescence of preformed PM domains, such as TEMs and 
lipid rafts (Krementsov et al., 2010; Hogue et al., 2011; Kerviel 
et al., 2013), creating a novel virus–induced PM domain used as 
a platform for HIV­1 assembly and budding. Therefore, our re­
sults suggest that HIV­1 assembly is functionally coupled to the 
trafficking and fusion of late endosomes with the PM.
The cytosolic accumulation of Pr55Gag in Rab27a­silenced 
cells is in agreement with previous studies showing that, in 
CD4+ T cell lines, depletion of PI(4,5)P2 by overexpression of 
phosphoinositide 5­phosphatase IV induces redistribution of 
Pr55Gag to a predominantly cytosolic localization (Monde et al., 
2011). In contrast, depletion of PM PI(4,5)P2 in HeLa cells 
induces Gag accumulation in CD63­positive MVEs (Ono et al., 
2004). Although the basis for these cell type–dependent differ­
ences is not clear, these observations indicate that the role 
played by endosomes in Gag membrane targeting and HIV­1 
assembly is different in CD4+ T cells and MDMs, as compared 
acidic structures, whereas its localization at the PM was mark­
edly reduced (Fig. 7 D). The biochemical interaction between 
CD63 and PI4KII was not altered in Rab27a­silenced cells 
(Fig. S5 A). Indeed, CD63 and PI4KII colocalized in enlarged 
endosomes, and both molecules were barely detected at the PM 
(Fig. 7 E). Live­cell visualization of CD63/PI4KII dynamics 
in Rab27a­silenced cells showed that the enlarged PI4KII­
positive endosomes did not undergo long­range movements 
toward the cell periphery (Video 2 and Fig. S5 B). Altogether, 
these observations suggest that Rab27a controls the intracel­
lular trafficking of CD63/PI4KII double­positive endosomes 
and the delivery of PI4KII to the PM, thus promoting PI(4)P 
and PI(4,5)P2 production at this location.
Slp2a is a Rab27a effector required for 
the delivery of PI4KII to the PM and for 
HIV-1 replication in CD4+ T cells
We next sought to identify the Rab27a effector proteins that are 
required for HIV­1 production. A total of seven out of the nine 
Rab27a effector proteins analyzed were found to be expressed 
in Jurkat cells (Table S1). The expression of each individual ef­
fector was silenced, and cells were then infected with HIV­1. 
Silencing of the genes EXPH5, SYTL2, and SYTL3, encoding 
the proteins Slac2b, Slp2a, and Slp3, respectively, reduced the 
extracellular release of p24 by ≥50% with ≥2 of the shRNA se­
quences that were used to target each gene (Fig. 8 A). The inhi­
bition of HIV­1 replication was consistent with a reduction in 
the expression levels of EXPH5 and SYTL3, as determined by 
quantitative RT­PCR (qPCR; Fig. 8 B) and of Slp2a, as deter­
mined by immunoblotting (Fig. 8 C). We then selected one 
shRNA targeting each gene to analyze the kinetics of HIV­1 
replication in large­scale cultures, using control and Rab27a­ 
silenced cells for comparative purposes. The inhibition of HIV­1 
replication in these experiments further confirmed the involve­
ment of Slp2a, Slac2b, and Slp3 in HIV­1 replication (Fig. 8 D). 
Furthermore, LSCM visualization showed that silencing the 
expression of Slp2a, Slp3, and Slac2­b led to a diffuse intra­
cellular Gag staining pattern accompanied by a dramatic reduc­
tion in the association of Pr55Gag with the PM (Fig. 8 E).
We then decided to further analyze the mechanistic 
basis of the inhibition of HIV­1 replication by Slp2a, an ef­
fector that has been previously shown to play an important 
role in vesicle docking, in particular in CD8+ T lymphocytes 
(Ménasché et al., 2008). First, we observed that Rab27a and 
the hematopoietic isoform of Slp2a, Slp2a­hem, colocalized 
on the same intracellular vesicular structures (Fig. 8 F). We 
next analyzed the subcellular distribution of CD63, PI4KII, 
PI(4)P, and PI(4,5)P2 in Slp2a­silenced cells. An intracellu­
lar accumulation of CD63­positive compartments concurrent 
with a decrease in PM levels of CD63 was observed (Fig. 8 G). 
Furthermore, we observed that PI4KII levels at the PM were 
dramatically reduced and that the enzyme accumulated at in­
tracellular structures (Fig. 8 H). Consistent with a reduction 
in PM levels of PI4KII, PM levels of PI(4)P (Fig. 8 I) and 
PI(4,5)P2 (Fig. 8 J) were reduced.
Analysis of CD63 and PI4KII interaction showed that 
both molecules still interacted in Slp2a­silenced cells (Figs. 8 K 
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Figure 8. Slp2a is a Rab27a effector required for PM delivery of PI4KII and HIV-1 assembly. (A) p24 production by Jurkat cells transduced with differ-
ent shRNAs targeting Rab27 effector genes and subsequently infected with a VSV-G–pseudotyped HIV-1 strain was evaluated at day 4 p.i. Data are the 
means ± SD of three independent experiments. Solid lines and dashed lines indicate 100% and 50%, respectively, of p24 production by control cells. 
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with HeLa cells. Along these lines, by using viral variants har­
boring mutations that block Gag­PI(4,5)P2 binding and target 
Gag to MVEs, it has been suggested that CD4+ T cells and 
MDMs rely more heavily on an endosome­to­PM trafficking 
pathway, as compared with HeLa cells (Joshi et al., 2009). In 
agreement with these results, we observed that whereas inhibi­
tion of Rab27a expression in HeLa cells induces a profound 
decrease in the docking of MVEs to the PM (Ostrowski et al., 
2010), the reduction in PI(4,5)P2 levels at the PM and, conse­
quently, HIV­1 assembly are not perturbed in this model cell 
line (unpublished data). The existence of different or alternative 
pathways of PI(4,5)P2 production and HIV­1 assembly in HeLa 
versus hematopoietic cells will be addressed in future studies.
Despite the unequivocal presence of tetraspanins at HIV­1 
exit sites, their role during HIV­1 assembly remains an open 
question (Chen et al., 2008; Ruiz­Mateos et al., 2008; Grigorov 
et al., 2009; Krementsov et al., 2009; Li et al., 2014). The dif­
ficulty in defining the role played by tetraspanins during the late 
stages of HIV­1 replication is probably a result of the fact that 
compensatory mechanisms are likely to take place between the 
more than 33 members of the tetraspanin family. Our results 
show that by promoting the fusion of late endosomes with the 
PM, Rab27a controls the levels of CD63 (and very likely other 
endosomal tetraspanins) at this location. The biochemical as­
sociation between CD63 and PI4KII suggests the localized 
production of PI(4)P at TEMs followed by the subsequent pro­
duction of PI(4,5)P2. These findings could thus represent the 
biochemical basis of the association of Pr55Gag with TEMs.
The different roles played by Rab27 are determined by the 
interaction with a different set of downstream effectors special­
ized in different functions. Herein, we found that in Jurkat cells, 
silencing of three different effectors, Slac2b, Slp2a, and Slp3, 
reduces Pr55Gag membrane association and HIV­1 replication. 
These results suggest a nonredundant and cooperative mode of 
action, in which the three Rab27 effectors work jointly in the 
Rab27a­controlled pathway. A similar mode of interaction has 
been observed in neuroendocrine PC12 cells, in which four 
Rab27 effectors, Slp4­a, Slac2­c, Rabphilin, and Noc2 contrib­
ute to the docking of granules to the PM (Desnos et al., 2003; 
Tsuboi and Fukuda, 2005, 2006). Further analysis of the role 
played by Slp2a allowed us to conclude that silencing this 
Rab27a effector phenocopies Rab27a­silenced cells, resulting 
in a reduction in PM levels of CD63, PI4KIIa, PI(4)P, and 
PI(4,5)P2. These results, together with previous studies showing 
that Slp2a is a critical docking factor (Ménasché et al., 2005), 
suggest that by recruiting Slp2a to CD63+ endosomes, Rab27a 
promotes the docking of these endosomes to the PM, allowing 
their fusion and the consequent delivery of PI4KIIa.
In conclusion, this study demonstrates that Rab27a regu­
lates PI(4,5)P2 levels at the PM of CD4+ T cells and in macro­
phage VCCs. Thus, Rab27a controls membrane association of 
Pr55Gag and, consequently, is required for HIV­1 replication.
Materials and methods
Cell lines, plasmids, lentiviral vectors, and HIV-1 viral strains
The human CD4+ T cell line Jurkat clone E6.1, the HIV-1 infection reporter 
human osteosarcoma cell line GHOST X4/R5, the HIV-1 BaL strain (using 
CCR5 coreceptor), and the HIV-1 IIIB strain (using CXCR4 coreceptor) were 
obtained from the AIDS Reagent Program, Division of AIDS, National Insti-
tute of Allergy and Infectious Diseases, National Institutes of Health. HEK 
293T cells were obtained from ATCC (CRL-11268).
The following plasmids were used: pEGFP-bos-CD63 and mCherry-
bos-CD63 encoding full-length CD63 in pEGFP-C1-bos or pmCherry-C1-bos 
backbone, respectively, under the Bos promoter (provided by G. Griffiths, 
Cambridge Institute for Medical Research, Cambridge, England, UK; Blott 
et al., 2001); GFP-P4M-SidM encoding the P4M domain from Legionella 
pneumophila fused to EGFP in the pEGFP-C1 backbone under cytomegalo-
virus (CMV) promoter (Addgene plasmid 51469; Hammond et al., 2014); 
pEGFP-C3-Rab27a encoding full-length Rab27a in the pEGFP-C3 back-
bone under the CMV promoter (Hume et al., 2001); pEGFP-N1-PI4K2A 
encoding full-length PI4K2A in the pEGFP-N1 backbone under the CMV 
promoter (provided by T. Balla, Eunice Kennedy Shriver National Insti-
tute of Child Health and Human Development, Bethesda, MD; Jović et al., 
2012); pEGFP-C1-Slp2a-hem encoding the hematopoietic form of Slp2-a 
in the pEGFP-C1 backbone under the CMV promotor (provided by G. de 
Saint Basile, Centre de Référence pour les Déficits Immunitaires Hérédi-
taires, Paris, France; Ménasché et al., 2008); Rab27a-2A-GFP encoding 
full-length Rab27a fused to a 2A peptide sequence from Thosea asigna 
virus followed by EGFP in pcDNA HIV SIN PZ-CG-FRW-DNP (Z-368) under 
the CMV promoter (provided by M. Zhang and R. Cron, University of 
Alabama at Birmingham, Birmingham, AL); pBR-NL4.3-IRES-EGFP-Nef+ en-
coding full-length HIV-1 in the pBR322 backbone under the control of viral 
long terminal repeat promoter (provided by F. Kirchhoff, Institute of Mo-
lecular Virology, Ulm University Medical Center, Ulm, Germany; Schindler 
et al., 2005); PH-GPF encoding the PH domain of phospholipase C 1 
subunit fused to GFP in pWPT-GFP under the EF1 promoter (provided by 
R. Galandrini, Istituto Pasteur-Fondazione Cenci-Bolognetti, Fondazione 
Eleonora Lorillard Spencer Cenci, Sapienza University, Rome, Italy; Micucci 
et al., 2006).
Lentiviruses were produced as described elsewhere (Moffat et al., 
2006). In brief, 2.5 × 103 HEK293T were seeded on a flat-bottom 96-well 
plate. 24 h later, cells were transfected with a mix of 100 ng pCMV-dR8.2 
DVpr, 100 ng of the target’s specific shRNA in the pLKO.1 backbone, 
and 10 ng pCMV–VSV-G per well, using X-tremeGENE HP DNA trans-
fection reagent (Roche), following the manufacturer’s recommendations. 
24 h later, medium was replaced, and supernatants containing lentiviral 
particles were collected at 48 and 72 h after transfection, precleared by 
centrifugation, aliquoted, and stored at 80°C.
The sequences of the shRNA used are: RAB27A#1, 5-CCGGCGG-
ATCAGTTAAGTGAAGAAACTCGAGTTTCTTCACTTAACTGATCCGTTTTT-3;  
RAB27A#2, 5-CCGGGCTGCCAATGGGACAAACATACTCGAGTATGTTT-
GTCCCATTGGCAGCTTTTT-3; RAB27A targeting the 3UTR region, 
5-GTACCGGGATCTTCTCTATGATTGATACCTCGAGGTATCAATCATA-
GAGAAGATCTTTTTTG-3; MLPH#1, 5-CCGGCCTTTAGGACAATGTT-
GTGTACTCGAGTACACAACATTGTCCTAAAGGTTTTTTG-3; MLPH#2, 
5-CCGGGTCTTCTGAGAGTCAGATCTTCTCGAGAAGATCTGACTCT-
CAGAAGACTTTTTTG-3; MLPH#3, 5-CCGGCTGATCTGTGAGAAAC-
AGCTACTCGAGTAGCTGTTTCTCACAGATCAGTTTTTTG-3; MLPH#4, 
(B) Inhibition of gene expression of EXPH5 and SYTL3 was determined by qPCR (n = 2). (C) Inhibition of Slp2a expression was determined by immunoblotting. 
(D) Kinetics of HIV-1 (strain IIIB; inoculum: 100 ng/ml) production by Jurkat cells stably transduced with control shRNA (closed circles), SYTL2 shRNA 
1 (open squares), EXPH5 shRNA1 (open circles), and SYTL3 shRNA 1 (open triangles). Rab27a-silenced cells were included for comparative purposes 
(closed squares). One representative experiment of two performed in triplicates is shown. (E) Intracellular distribution of Gag in control or Slac2-b–, Slp2a-, 
and Slp3-silenced cells was analyzed by LSCM at day 7 p.i. (F) LSCM visualization of cells transiently transfected with dsRed-Rab27a and Slp2a-GFP. 
(G–J) LSCM of live control and Rab27a-silenced cells stably expressing CD63-GFP (G), PI4KIIa-GFP (H), GFP-P4M (I), and PH-GFP (J). Representative confo-
cal images (left) and transmitted light images (right) are shown. Quantifications were performed by blinded observers on a per-cell basis, in ≥50 cells of 
each condition. (K) LSCM of live Slp2a-silenced Jurkat cells transiently transfected with PI4KII-GFP and mCherry-CD63 plasmids. Error bars show SDs. 
KD, knockdown. Bars, 2 µm.
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mouse anti–HIV-1 p24 (KC57-FITC; Beckman Coulter); rabbit anti–HIV-1 
gp41 (Fitzgerald); Alexa Fluor 594–labeled donkey anti–mouse, Alexa 
Fluor 488–labeled donkey anti–mouse, biotin-labeled donkey anti–human, 
and Alexa Fluor 594–labeled donkey anti–rabbit (Jackson ImmunoResearch 
Laboratories, Inc.); rabbit anti–human Slp2-a (provided by M. Fukuda, Tohoku 
University, Katahira, Miyagi Prefecture, Japan) was obtained by immuniz-
ing rabbits with GST-Slp2-a-SHD followed by affinity purification by expo-
sure to antigen-bound Affi-Gel 10 beads (Imai et al.,2004); rabbit anti–rat 
PI4KII (full length; Guo et al., 2003) was provided by P. De Camilli (Yale 
University, New Haven, CT); and recombinant human anti–HIV-1 gp120 
monoclonal antibody (2G12, produced in CHO cells and subsequently pu-
rified by protein A affinity chromatography) from H. Katinger (Buchacher 
et al., 1994; Trkola et al., 1996) and mouse anti–HIV-1 p24 monoclonal 
antibody (clone 183-H12-5C) from B. Chesebro (Chesebro et al., 1992) 
were obtained through the National Institutes of Health AIDS Reagent Pro-
gram, Division of AIDS, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health.
Patient with GS
The pediatric patient with GS type 2 carries a homozygous RAB27A exon 
3 and 4 deletion leading to a frameshift and a premature stop codon. 
PBMCs were obtained from the patient and the corresponding age-matched 
controls, who had provided written informed consent in accordance with 
procedures at Institut National de la Santé et de la Recherche Médicale 
(Paris, France).
Preparation of viral stocks
The HIV-1 BaL isolate was propagated onto primary macrophages and col-
lected from the culture supernatants. The HIV-1 IIIB isolate was obtained 
from H9/HTLV-IIIB supernatants (Popovic et al., 1984). The viruses were 
concentrated by ultracentrifugation at 28,000 rpm for 90 min at 4°C 
(L7-65 ultracentrifuge; Beckman Coulter), and the virus pellet was sus-
pended in RPMI 1640 medium. The levels of p24 antigen were determined 
by ELISA (InnoGenetics), and virus input into assays was a function of p24 
antigen concentration.
Degranulation assay and CD63 cell surface translocation
For degranulation assays, 2 × 105 control or Rab27a-silenced primary 
CD4+ T cells were cultured at 37°C in 200 µl complete RPMI contain-
ing 10 µM monensin and 5 µg/ml FITC-conjugated anti-CD63 or isotype 
control. When indicated, cells were stimulated for 20 min with 25 ng/ml 
PMA (Sigma-Aldrich) and 1 µg/ml ionomycin (Sigma-Aldrich). Cells were 
washed and analyzed by FACS.
HIV-1 infection
Macrophages (5 × 104/0.1 ml) were infected with HIV-1 BaL strain 
(50 ng/ml) for 1.5 h at 37°C. Cells were subsequently washed and in-
cubated for different periods. Jurkat cells, PBMCs, and purified CD4+  
T lymphocytes (3 × 104/0.1 ml) were infected by the addition of either HIV-1 
IIIB strain (50 ng p24/ml; low MOI) or spinoculated with VSV-G–pseudotyped 
NL4-3-IRES-EGFP (50 ng p24/ml [low MOI] or 200 ng p24/ml [high MOI]) 
in the presence of 8 µg/ml of polybrene.
In the screening for Rab27a effector proteins, the number of puromycin-
resistant Jurkat cells transduced with the different shRNAs was measured using 
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega). 
An equal number of cells were then infected with VSV-G–pseudotyped NL4-3-
IRES-EGFP (20 ng p24/ml) to ensure a uniform MOI in all conditions.
Quantification of HIV-1 production
HIV-1 p24 released into the cell culture supernatants was quantified using 
the Innotest HIV-1 Ag mAb Screening 3 kit (InnoGenetics). The number of 
living cells present in each well was evaluated using CellTiter 96 AQueous 
Non-Radioactive Cell Proliferation Assay.
Infectivity assay
For infectivity assays, control and Rab27a-silenced cells were infected with 
HIV-1 strain IIIb. At day 10 after infection, cell culture supernatants were 
collected, and their content of p24 was determined by ELISA to allow 
the normalization for equal amounts of p24. The volume of supernatant 
equivalent to 10 ng p24 was incubated with 20,000 GHOST cells for 
48 h, and the percentage of GFP-positive GHOST cells was determined 
by FACS analysis.
5-CCGGGATCGGAAATCAGTGTACCGACTCGAGTCGGTACACTG-
ATTTCCGATCTTTTTTG-3; MLPH#5, 5-CCGGCAGTACAACAGGACC-
ACAGATCTCGAGATCTGTGGTCCTGTTGTACTGTTTTTTG-3; EXPH5#1, 
5-CCGGCCGCTTAATATCTATGAGGATCTCGAGATCCTCATAGATAT-
TAAGCGGTTTTTTG-3; EXPH5#2, 5-CCGGCCGCACACAGATAAAT-
CCAATCTCGAGATTGGATTTATCTGTGTGCGGTTTTTTG-3; EXPH5#3, 
5-CCGGCCCAAACTAGAAGAAGTTCTTCTCGAGAAGAACTTCTTCT-
AGTTTGGGTTTTTTG-3; EXPH5#4, 5-CCGGCCTCTATCGTTCAAA-
GAGTTTCTCGAGAAACTCTTTGAACGATAGAGGTTTTTTG-3; EXPH5#5, 
5-CCGGGCCAAGAGAAAGGACATTCTTCTCGAGAAGAATGTCCTTT-
CTCTTGGCTTTTTTG-3; SYTL1#1, 5-CCGGCCTGGACACTTACGTAC-
AATGCTCGAGCATTGTACGTAAGTGTCCAGGTTTTTG-3; SYTL1#2, 
5-CCGGGGCGGTGAAGAAACGGAATCTCTCGAGAGATTCCGTTTCTT-
CACCGCCTTTTTG-3; SYTL1#3, 5-CCGGTGACCTTGTCCGAGCGTC-
TATCTCGAGATAGACGCTCGGACAAGGTCATTTTTG-3; SYTL1#4, 
5-CCGGTCAACGAGACTCTCCGGTACTCTCGAGAGTACCGGAGAG-
TCTCGTTGATTTTTG-3; SYTL1#5, 5-CCGGACATCTTTCTGGGCGAA-
GTTGCTCGAGCAACTTCGCCCAGAAAGATGTTTTTTG-3; SYTL2#1, 
5-CCGGTAACGAAATACTGCGGTATAACTCGAGTTATACCGCAG-
TATTTCGTTATTTTTG-3; SYTL2#2, 5-CCGGCTTAGCAGCAGCGGATG-
TAAACTCGAGTTTACATCCGCTGCTGCTAAGTTTTTG-3; SYTL2#3, 
5-CCGGATTTGGCATCGGGATACATTTCTCGAGAAATGTATCCCGAT-
GCCAAATTTTTTG-3; SYTL2#4, 5-CCGGGTCGCAGAAAGATACTC-
AAAGCTCGAGCTTTGAGTATCTTTCTGCGACTTTTTG-3; SYTL2#5, 
5-CCGGTCAACCACACTATGGTGTATGCTCGAGCATACACCATAGTGT-
GGTTGATTTTTG-3; SYTL3#1, 5-CCGGGAGAAATACGAAGACAGC-
GTTCTCGAGAACGCTGTCTTCGTATTTCTCTTTTTTG-3; SYTL3#2, 
5-CCGGCGGAGAGTGTTTCTTGGAGAACTCGAGTTCTCCAAGAAA-
CACTCTCCGTTTTTTG-3; SYTL3#4, 5-CCGGGCACCTTGAACTCATTT-
GTTACTCGAGTAACAAATGAGTTCAAGGTGCTTTTTTG-3; SYTL3#5, 
5-CCGGCAAATGCTCTACTAACCCTATCTCGAGATAGGGTTAGTA-
GAGCATTTGTTTTTTG-3; MYRIP#1, 5-CCGGGCCAAATAAGTGCA-
AAGATTTCTCGAGAAATCTTTGCACTTATTTGGCTTTTTG-3; MYRIP#2, 
5-CCGGCCCAGGTACAAACCATAGATACTCGAGTATCTATGGTTTGTA-
CCTGGGTTTTTG-3; MYRIP#3, 5-CCGGGCTTCGACATTCTAGGAGG-
AACTCGAGTTCCTCCTAGAATGTCGAAGCTTTTTG-3; MYRIP#4, 
5-CCGGGCTGTACGAGTTAGCAATGAACTCGAGTTCATTGCTAAC-
TCGTACAGCTTTTTG-3; MYRIP#5, 5-CCGGCCTGCAGAAGATTATAC-
GAAACTCGAGTTTCGTATAATCTTCTGCAGGTTTTTG-3; RPH3AL#1, 
5-CCGGGGCTATCTCCGTTGCTATATTCTCGAGAATATAGCAACGGA-
GATAGCCTTTTTG-3; RPH3AL#2, 5-CCGGAGGGACCGGAAAGGC-
GACAAACTCGAGTTTGTCGCCTTTCCGGTCCCTTTTTTG-3; RPH3AL#4, 
5-CCGGTAGAGGACAGACTCCCATCCACTCGAGTGGATGGGAGT-
CTGTCCTCTATTTTTG-3; RPH3AL#5, 5-CCGGCAGGAAGAAAGTCTG-
CACCAACTCGAGTTGGTGCAGACTTTCTTCCTGTTTTTG-3; RPH3AL#6, 
5-CCGGGCAGTGAGCAAAGAGAGGTCTCTCGAGAGACCTCTCTTT-
GCTCACTGCTTTTTG-3; SYTL4#1, 5-CCGGCCTCACTACAACCATA-
CATTTCTCGAGAAATGTATGGTTGTAGTGAGGTTTTTG-3; SYTL4#2, 
5-CCGGCGGGACACTGTTAATCCACTACTCGAGTAGTGGATTAACAGT-
GTCCCGTTTTTG-3; SYTL4#3, 5-CCGGCCTCCCTTTACATGGAA-
AGATCTCGAGATCTTTCCATGTAAAGGGAGGTTTTTG-3; SYTL4#4, 
5-CCGGCGCCAAGGAAATAGAGTTGAACTCGAGTTCAACTCTATTTC-
CTTGGCGTTTTTG-3; SYTL4#5, 5-CCGGGAGTACACTAAATCTGT-
GATACTCGAGTATCACAGATTTAGTGTACTCTTTTTG-3; UNC13D#1, 
5-CCGGGCTTTGCTACATGAACACCAACTCGAGTTGGTGTTCATGTA-
GCAAAGCTTTTTTG-3; UNC13D#2, 5-CCGGGAGACCTTCATCCTGGAG-
TTTCTCGAGAAACTCCAGGATGAAGGTCTCTTTTTTG-3; UNC13D#3, 
5-CCGGCTTCATGATTACCGTCAAGTTCTCGAGAACTTGACGGTAAT-
CATGAAGTTTTTTG-3; UNC13D#4, 5-CCGGGATCTTCCACAATACCCTC-
AACTCGAGTTGAGGGTATTGTGGAAGATCTTTTTTG-3; UNC13D#5, 
5-CCGGGATGTGCAAGATGAAGGCCTTCTCGAGAAGGCCTTCATCTTG-
CACATCTTTTTTG-3; TBC1D10A#1, 5-CCGGGAGTGAGGACACCTACT-
TGTACTCGAGTACAAGTAGGTGTCCTCACTCTTTTTTG-3; TBC1D10A#2, 
5-CCGGCAAGGTGAAGTTACAGCAGAACTCGAGTTCTGCTGTAACTT-
CACCTTGTTTTTTG-3; TBC1D10A#3, 5-CCGGCCATATAACTACACGG-
TTCATCTCGAGATGAACCGTGTAGTTATATGGTTTTTTG-3; TBC1D10A#4, 
5-CCGGGTTCCCATTCCATGAGATGTTCTCGAGAACATCTCATGGAAT-
GGGAACTTTTTTG-3; and TBC1D10A#5, 5-CCGGCGCTCCTCTATAT-
GACAGAATCTCGAGATTCTGTCATATAGAGGAGCGTTTTTTG-3.
Antibodies
The following antibodies were used: phycoerythrin (PE)-labeled mouse 
anti–human CD81 (BD); PE-labeled mouse anti–human CD63 (Invitrogen); 
rabbit anti–human Rab27a and rabbit anti–human -actin (Synaptic Systems); 
PE-labeled mouse anti–humanCD317/Tetherin (eBioscience); FITC-labeled 
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Blots were revealed using SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Fisher Scientific). Intensity of the bands was quantified using 
the software ImageJ (National Institutes of Health).
Cell fractionation
Subcellular fractionation was performed using the Qproteome Cell Com-
partment kit, according to the manufacturer’s instructions (QIAGEN). 
Alternatively, cell fractions were isolated by differential centrifugation as 
described previously (Cox and Emili, 2006). In brief, 107 Jurkat cells were 
washed twice in PBS and attached extracellular virus was eliminated by 
incubating the cells with trypsin for 5 min at 37°C. After washing, cells 
were resuspended in 250 mM sucrose, 50 mM Tris-HCl, pH 7.4, and 
5 mM MgCl2 containing protease inhibitor cocktail (Roche). This suspen-
sion was passed 40 times through a 29-guage needle to lyse the cells, cen-
trifuged to eliminate nuclei and cells debris, and then ultracentrifuged for 
1 h at 100,000 g. The supernatant of this ultracentrifugation represents the 
cytosolic proteins, and the pellet represents the membrane-bound proteins. 
This pellet was resuspended in 0.5 ml of 20 mM Tris-HCl, 0.4 M NaCl, 
15% glycerol, and 1.5% Triton X-100, incubated for 1-h shaking at 1,400 
rpm and 4°C, and centrifuged at 9,000 g for 30 min. The supernatant 
contained the isolated membrane proteins.
Immunoprecipitation of GFP-CD63
For immunoprecipitation of GFP-CD63, 107 GFP-CD63–transfected cells 
were lysed in immunoprecipitation buffer (1% Brij 99, 10 mM Tris/HCl, 
pH 7.4, 150 mM NaCl, and 5 mM EDTA, with Roche protease inhibitor 
cocktail) for 1 h at 4°C. Precleared supernatants were then immunoprecipi-
tated with GFP-Traps or uncoated agarose beads (as control for unspecific 
bound) according to manufacturer’s instructions (ChromoTek). Coprecipita-
tion of PI4KII was revealed by immunoblotting.
qPCR
RNAs were isolated with TRIzol reagent (Life Technologies), and 200-ng 
RNAs were reverse transcribed with M-MLV Reverse transcription (Invitro-
gen). 1/10th cDNA was used for each PCR reaction, performed with SYBR 
green (Applied Biosystems) on a real-time thermal cycler (PRISM 7500; 
Applied Biosystems). Cycle thresholds (Ct’s) were normalized to the Ct of 
GAPDH, and fold enrichments were calculated as compared with the 
values from control shRNA-transduced cells.
Cell-to-cell transmission assay
Jurkat cells (donor cells) were infected with the HIV-1 IIIB strain. At day 10 p.i, 
the percentage of infected cells was determined by intracellular staining of 
p24 antigen followed by FACS analysis. To have equal numbers of control 
and Rab27a-silenced HIV-1–infected Jurkat cells, cells were diluted with 
noninfected control or Rab27a-silenced cells, respectively, to have a total 
of 4,800 HIV-1–infected donor cells present in a total of 80,000 cells (6%) 
for each category. Next, cells were added to wells containing 30,000 
adherent GHOST cells (target). Donor and target cells were co-cultured 
at 37°C for 3 h before Jurkat cells were removed by extensive washes. 
HIV-1 transmission was evaluated 48 h later by analyzing the percentage 
of GFP-expressing GHOST cells. Alternatively, donor and target cells were 
separated by a 0.2-µm-diameter pore to allow viral transmission without 
cell-to-cell contact.
Flow cytometry
For surface labeling, cells were stained with antibodies diluted in PBS–
0.5% BSA on ice. For intracellular staining, cells were fixed and permeabi-
lized using Cytofix/Cytoperm reagents (BD) and stained with antibodies 
diluted in permeabilization buffer. Cells were acquired on a FACSCanto 
(BD) and analyzed using FACSDiva software (BD).
Fluorescence microscopy
105 cells were seeded on poly-l-lysine–coated glass coverslips for 60 min, 
fixed in 4% paraformaldehyde, quenched with 0.1 M glycine, permea-
bilized in PBS–0.2% BSA–0.05% saponin, and incubated with primary 
antibodies, which were subsequently detected with Alexa Flour 594–labeled 
donkey anti–mouse, Alexa Fluor 488–labeled donkey anti–mouse, or Alexa 
Fluor 594–labeled donkey anti–rabbit (Jackson ImmunoResearch Laborato-
ries, Inc.) secondary antibodies, as indicated. The coverslips mounted with 
Fluoromount-G (SouthernBiotech) were examined under a confocal micro-
scope (FluoView FV1000; Olympus) using a Plan Apochromat 60× 1.42 
NA oil immersion objective. Images were analyzed using the FV10-ASW 
Lentiviral transduction, gene silencing, and transfection of Jurkat cells
A total of 30,000 Jurkat cells were transduced with lentiviral vectors by 
spinoculation (2,200 rpm at 90 min for 37°C) in the presence of 8 µg/ml 
of polybrene. After 48 h, transduced cells were selected by the addition 
of 3 µg/ml puromycin. Transfection of Jurkat cells was performed using 
X-tremeGENE HP DNA (Roche) following the manufacturer’s instruction.
Primary cells transduction and gene silencing
To silence gene expression in macrophages, monocytes were isolated 
from buffy coats of healthy anonymous donors from the Blood Center of 
the Mendez Hospital in Buenos Aires, Argentina. Cells were transduced 
with the corresponding lentiviral vector together with virus-like particles 
containing the protein VPx from simian immunodeficiency virus (provided 
by N. Manel, Institut Curie, Paris, France) in the presence of 30 ng/ml 
rHuGM-CSF and 2.5 µg/ml polybrene for 5 d following a recently pub-
lished protocol (Satoh and Manel, 2013). Transduced cells were selected 
by the addition of 30 µg/ml puromycin. To silence gene expression in 
primary T lymphocytes, either PBMCs or isolated CD4+ T lymphocytes 
(purified by using a CD4+ T Cell Isolation kit [Miltenyi Biotec]) were 
seeded at 2 × 106 cells/ml and stimulated with either 1 µg/ml phyto-HA 
or with anti-CD3/CD28 beads for 3 d in culture medium supplemented 
with 10 U/ml IL-2. Subsequently, cells were spinoculated as described in 
the previous section. After spinoculation, 5 ng/ml rIL-2 was added and 
refreshed every 3 d.
HIV-1 attachment and entry
For HIV attachment and entry measurements, 50,000 Jurkat cells were 
infected with HIV-1 strain IIIb (50 ng/ml p24) for 1.5 h at 4°C (attachment) 
or 37°C (attachment + entry). Cells were then extensively washed (five 
times) to remove unbound viral input and lysed with radioimmunoprecipi-
tation assay buffer. Total cell protein was calculated using bicinchoninic 
acid, and all samples were normalized for protein content before quantifi-
cation of cell-associated p24 by ELISA. Viral attachment (4°C) corresponds 
to p24 amount measured in samples kept at 4°C, and viral entry cor-
responds to the difference between p24 from samples kept at 37°C and 
the ones at 4°C.
Single cycle viral entry assay
A total of 30,000 Jurkat cells were infected with two doses of HIV-1 strain 
IIIb (50 and 500 ng/ml) for 6 h at 37°C. Cells were then washed to re-
move extracellular virions, and 5 µM AZT (zidovudine) was added to the 
culture medium to prevent secondary replication cycles and maintained 
throughout the study. Alternatively, cells were treated with AZT before HIV-1 
infection to evaluate the efficiency of the drug to inhibit HIV-1 replication. 
Viral entry was assessed by quantifying the percentage of HIV-1–infected 
cells at 48 h p.i.
HIV-1 release assay
3 × 104/0.1 ml Jurkat cells were spinoculated with a high MOI of VSV-G– 
pseudotyped HIV-1. 48 h later, 1 ml cell culture supernatants were col-
lected, ultracentrifuged (100,000 g; 90 min), and resuspended in 20 µl 
of immunoblot loading buffer. Cells were extensively washed and lysed. 
20 µg of cell lysate and the totality of the pelleted supernatant were ana-
lyzed by immunoblotting using p24 antibodies and actin as a loading 
control for the cell lysates.
Rab27a shRNA rescue experiments
To rescue the Rab27a knockdown phenotype, exogenous Rab27a was 
expressed in Jurkat cells in which endogenous Rab27a expression was 
silenced by using an shRNA targeting the 3UTR of the Rab27a gene. 
Expression of exogenous Rab27a was achieved by transducing the cells 
with a lentiviral vector encoding human Rab27a fused to a 2A peptide 
sequence from T. asigna virus followed by GFP, thus allowing simultaneous 
expression of Rab27a and GFP. Cells expressing the exogenous Rab27a 
were identified by visualizing GFP expression in microscopy experiments. 
Alternatively, to analyze HIV-1 replication, GFP-expressing cells were 
FACS sorted and subsequently infected with HIV-1.
Cell lysates and immunoblot
Cells were lysed in precooled radioimmunoprecipitation assay buffer (1% 
Triton X-100, 0.1% SDS, 50 mM Tris, pH 7.5, 150 mM NaCl, and 0.5% 
sodium deoxycholate), supplemented with a cocktail of antiproteases (Roche), 
and cleared from nuclei by centrifugation at 15,000 g for 5 min. Equal 
amounts of protein extracts were separated on 4–12% SDS-PAGE, blotted 
on Polyvinylidene Fluoride Transfer Membrane (Thermo Fisher Scientific). 
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Online supplemental material
Fig. S1 shows rescue experiments for Rab27a functionality. Fig. S2 shows 
that Rab27a silencing alters neither HIV-1 entry nor tetherin expression. 
Fig. S3 shows a defect in CD63 translocation to the cell surface in Rab27a-
silenced cells in which granule secretion was induced by PMA-ionomycin 
stimulation. Fig. S4 shows CD63 and CD81 distribution in Jurkat cells. 
Fig. S5 shows the biochemical association between PI4KII and CD63 in 
control, Rab27a-silenced cells, and Slp2a-silenced cells. Table S1 shows 
qPCR analysis of the expression of Rab27 effector proteins in Jurkat cells. 
Video 1 shows localization and dynamics of mCherry-CD63 and GFP-
PI4KII in control Jurkat cells. Video 2 show localization and dynamics 
of mCherry-CD63 and GFP-PI4KII in Rab27a-silenced Jurkat cells. Video 
3 shows localization and dynamics of mCherry-CD63 and GFP-PI4KII in 
Slp2a-silenced Jurkat cells. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201409082/DC1.
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software (Olympus). In Figs. 3 C, 4 C, 5, and 6 (E, F, and H), levels were 
adjusted using Photoshop 7 (Adobe) for better visualization according to 
the guidelines for the presentation of digital data.
Fluorescence images of live or fixed cells shown in Figs. 2, 6 A, 7, 
8 (F–I), S5 B, and Videos 1–3 were acquired in a spectral confocal micro-
scope (FluoView FV1000; acquisition software FV10-ASW 2.0), at room 
temperature, using a 60× U Plan S Apochromat, NA 1.35 oil immersion 
objective, in RPMI 1640 medium supplemented with 10% FCS and 10 nM 
Hepes. Images and videos were analyzed using FIJI (National Institutes of 
Health) and Matlab (The MathWorks, Inc.) software, respectively.
In Figs. 3 A and 5 C, images were acquired at room temperature 
using a motorized upright wide-field microscope (DMRA2; Leica) equipped 
for image deconvolution. Acquisition was performed using a 100× objec-
tive (Plan Apochromat HCX, 1.4 NA) and a high-sensitive cooled interlined 
charge-coupled device camera (CoolSNAP HQ; Roper Scientific). Z posi-
tioning was accomplished by a piezoelectric motor (Linear Variable Differ-
ential Transformers LVDT; Physik Instrument), and a z series of images was 
taken (an image every 0.2 µm). Images were acquired with MetaMorph 
software (Molecular Devices).
Image processing
In Figs. 3 A and 5 C, deconvolution was performed automatically using 
an iterative and measured point spread function–based algorithm method 
(Gold–Meinel) on batches of image stacks, as a service proposed by the 
Bioimaging Cell and Tissue Core Facility of the Institut Curie, as described 
in Sibarita (2005). Image panels were assembled with Photoshop; no 
digital manipulation was applied except for adjustment of brightness and 
contrast in Figs. 3 (A and B), 4 C, 5, 6 (F and H), and 8 (E and F) using 
ImageJ software.
Phospholipid labeling and analysis
2 × 106 Rab27a-silenced or control cells were pulsed with 25 µCi/ml of 
[32P]orthophosphate during 45 min either in TBS buffer or in RPMI 1640 
media. Cells were washed tree times with cold TBS, and phosphoinosit-
ide phospholipids were extracted by a single-step acidic extraction (Lloyd 
et al., 1972). In brief, 1 ml cell suspension was mixed with 3.75 ml chlo-
roform/methanol/HCl (12 N; 40:80:1 vol/vol/vol). After mixing, 1.25 ml 
chloroform was added for 5–10 s followed by 1.25 ml of water with 
mixing for 5–10 s. The biphasic mixture was centrifuged at 1,000 rpm 
for 10 min, and the chloroform layer was transferred to another tube and 
dried (Vickers et al., 1982).
For TLC separation of phosphoinositide phospholipids, Silica Gel 
60 TLC plates (Merck) were treated with a solution of 1% potassium oxa-
late in methanol/water (2:3) and warmed to 110°C for 30 min before use. 
TLC plates were developed by using a 1D, two-solvent system consisting of 
mixtures of chloroform/methanol/acetic acid/water, 25:15:8:2 vol/vol/
vol/vol for the first run and 25:15:16:2 vol/vol/vol/vol for the second. 
After TLC plates were dried, they were exposed to the autoradiography 
film, incubated during 24–72 h at 70°C, and developed. In parallel, 
polyphosphoinositide standards obtained from Echelon were run under the 
same conditions and stained by iodine spraying for visualization. The Rf 
(relative migration factor) for each standard was calculated and used for 
the identification of the radioactive phospholipid samples developed by 
autoradiography according to previous studies (Bussolino et al., 2001).
Statistical analyses
Data were analyzed using Prism (GraphPad Software). Normality of the 
data was tested using the Kolmogorov–Smirnov test. Based on the normal-
ity test, either one-way analysis of variance followed by Tukey’s after test 
or Kruskal–Wallis followed by Dunn’s after test were used for multiple com-
parison analyses. Values are given as means ± SD. For the colocalization 
analysis, Manders overlap coefficient was calculated as previously de-
scribed (Manders et al., 1993). Manders colocalization maps were ob-
tained by imaging the contribution Ri of each pixel i of the images to the 
Manders overlap coefficient, calculated following
	 R
S i S i
S k S k
i
k k
= ×
×∑ ∑
1 2
1 22 2( ) ( )
, 	
where S1i represents the signal intensity of pixels in channel 1, and S2i 
represents the signal intensity of pixels in channel 2. This analysis was 
performed through a Matlab-written previously described algorithm (Villalta 
et al., 2011).
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